Compare PBT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBT | ERAS |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.1M | 927.7M |
| IPO Year | N/A | 2021 |
| Metric | PBT | ERAS |
|---|---|---|
| Price | $17.60 | $3.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.71 |
| AVG Volume (30 Days) | 87.7K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $17,266,423.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $53.84 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.01 | $1.01 |
| 52 Week High | $20.46 | $3.62 |
| Indicator | PBT | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 71.90 |
| Support Level | $17.13 | $3.15 |
| Resistance Level | $18.73 | $3.48 |
| Average True Range (ATR) | 0.77 | 0.22 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 17.86 | 99.81 |
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.